Vinpocetine
- Generic Name
- Vinpocetine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H26N2O2
- CAS Number
- 42971-09-5
- Unique Ingredient Identifier
- 543512OBTC
- Background
Vinpocetine has been investigated for the treatment of Epilepsy.
- Indication
用于改善脑出血、脑梗死及脑动脉粥样硬化所致的多种神经或精神症状，如眩晕、头痛、记忆力减退、行为障碍、精神不振、抑郁、四肢麻木、语言障碍等。
- Associated Conditions
- Cerebrovascular stenosis, Neurological Disorders
- Associated Therapies
- -
Dose Escalation Study of Vinpocetine in Healthy Volunteers
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 20
- Registration Number
- NCT06635746
Clinical Outcome of Vinpocetine in Diabetic Nephropathy
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 64
- Registration Number
- NCT06441591
- Locations
- 🇪🇬
Ain Shams Hospitals, Cairo, Abbasseya, Egypt
🇪🇬Ain Shams University Hospital, Cairo, Abbasseia, Egypt
Vinpocetine Inhibits NF-κB-dependent Inflammation in Acute Ischemic Stroke Patients
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-08-25
- Last Posted Date
- 2016-08-25
- Lead Sponsor
- Tianjin Medical University General Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT02878772
Cognitive Effects of Vinpocetine in Healthy Adults and Patients With Epilepsy
- First Posted Date
- 2013-12-16
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 30
- Registration Number
- NCT02011971
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath